May 5th, 2026

The call balances strong commercial execution, clear revenue guidance (reaffirmed $730M–$760M for 2026), rapid pipeline progress (two near-term PDUFAs and promising long-term GTX-102 data with Bayley-4 and MDRI signals), and manufacturing/launch readiness against meaningful near-term financial pressure (Q1 net loss of $185M, $197M cash used in operations, high operating expenses and restructuring charges). Management presented a credible path to profitability in 2027 with planned R&D/SG&A reductions and assumed PRV monetization, but timing uncertainty for Phase 3 readouts, quarter-to-quarter ordering variability and execution risks around launches and PRV realization remain. Overall the positives around product performance, global commercialization scale, and upcoming catalysts outweigh the near-term financial and execution risks.

Company Guidance

On the call management reaffirmed 2026 revenue guidance of $730–760 million (8%–13% growth vs. 2025), excluding potential launch revenue, and reiterated a path to profitability in 2027; Crysvita revenue guidance is $500–520 million and Dojolvi $100–110 million for 2026, while combined R&D and SG&A are expected to be flat to down low single digits vs. 2025 (with a targeted ≥15% reduction vs. 2025 in 2027). Q1 results included total revenue of $136 million (Crysvita $93M — NA $39M, Latin America & Turkey $46M, Europe $8M; Dojolvi $18M; Evkeeza $18M, +64% YoY; Mepsevii $7M), total operating expenses of $305M (cost of sales $30M; R&D+SG&A $275M) which included $30M stock‑based comp and $30M restructuring charges, net loss of $185M or $1.84 per share, cash and equivalents of $534M as of March 31, and net cash used in operations of $197M (including $38M for UX143 manufacturing and $5M severance) with operating cash use expected to decline in later quarters. They plan to monetize two PRVs modeled at a little over $100M each (with upside potential), target PDUFA dates for DTX401 on Aug 23, 2026 and UX111 on Sept 19, 2026, and highlighted commercial scale (sales in >35 countries) and patient counts (Crysvita >950 patients in LATAM with ~30 starts in Q1; Dojolvi >675 reimbursed in NA and ~300 in Europe; Evkeeza ~370 patients across 18 countries).